Klinik Araştırmalar Derneği Uzaktan Eğitim Programları KADUZEM Hakkında Detaylı Bilgi İçin

Son Haberler

Importance of postmarketing surveillance for safety..

  • 04 Feb 18

According to a study published in JAMA, among the 222 novel drugs approved by FDA between 2001-2010 and followed to 2017, 71 (32%) of them had new safety issues. Biologics, psychiatric therapeutics, and accelerated and near–regulatory deadline approval had the largest number of new safety warnings.


Payment and Reimbursement to Research Subjects - FDA Information Sheet

  • 02 Feb 18

FDA published an information sheet for Payment and Reimbursement to Research Subjects.


EORTC organised an Independent Data Review Committee (IDRC) workshop..

  • 02 Feb 18

EORTC organised an Independent Data Monitoring (IDRW) Committee workshop in the EORTC Headquarters in Brussels. Dr. Hamdi Akan from Turkey was there.


PubMed funding problem!

  • 01 Feb 18

One of the largest scientific database software that contains more than 27 million citations; PUBMED is facing funding problems.


FDA Launches Pilot Program to Improve Transparency of Clinical Trial Information..

  • 22 Jan 18

FDA has launched a new pilot program that will evaluate whether disclosing certain information within clinical study reports (CSRs) following approval of a new drug application (NDA) enhances public access to drug approval information. A CSR is a portion of a drug file, related to a clinical trial, that includes summaries of the bottom-line information on the methods and results of a clinical trial.


Efficacy of new Cancer drugs: do they work?

  • 10 Jan 18

Among new cancer drugs approved between 2003 and 2013, up to one in five have no benefit for the patient. Fewer than half (43%) of the cancer drugs evaluated were found to increase Overall Survival (OS) by at least 3 months. A further 11% of the 53 drugs evaluated increased OS by less than 3 months, while 15% had an indeterminate effect on OS. The remaining 16 (30%) cancer drugs did not demonstrate an increase in OS over alternative treatments,


FDA approvals hit 21 year high in 2017..

  • 04 Jan 18

U.S. drug approvals hit a 21-year high in 2017, with 46 novel medicines winning a green light -- more than double the previous year -- while the figure also rose in the European Union. World?s biggest drugmakers saw average returns on their research and development spending fall, reflecting more competitive pressures and the growing share of new products now coming from younger biotech companies.


Happy new year..

  • 25 Dec 17

Clinical Research Association wishes a new year full of happiness and peace..


Klinik Araştırmalar Derneği'nin yeni yenilikci aktiviteleri

Toplamda 25'den fazla olan aktivitelerinden bazıları aşağıdadır.